Samsung Biologics Inks Partnership Deal with GreenLight Biosciences for Manufacturing Messenger RNA Vaccine

The partnership of GreenLight Biosciences, the US Biotechnology firm with the Korean biotechnology company will boost its production capacity of messenger RNA vaccine. The messenger RNA vaccine will be produced at commercial stage. GreenLight Biosciences manufactures products combine with Ribonucleic acid focused at human health and agricultural usage.

The partnership aims to increase the production messenger RNA vaccine of GreenLight for phase III clinical trials and further seek regulatory approval for producing it at commercial scale. The partnership with Samsung Biologics will leverage existing manufacturing process of GreenLight and technology up-gradation.

Both the companies aim to enable vaccine equity by producing big quantities of messenger RNA vaccine doses that will serve billions of people across the world. This supports the key objective of GreenLight, to increase production capacity of covid-19 vaccines and vaccinate people against covid-19. The company not just aims to increase production capacity of covid-19 vaccine but also increase vaccine manufacturing capacity for other infectious diseases and serve the ongoing global health needs.

While stating about the partnership, the CEO of Greenlight said, he is delighted to partner with Samsung Biologics. The CEO stated that the company is open to develop vaccines for US as well as the developed countries. GreenLight Biosciences is aimed at developing sustainable solutions ccommodating client needs. It manufactures products combine with Ribonucleic acid focused at human health and agricultural usage